EUROPEAN UNION

INTRA

Part I: Description of consignment

I.1. Consignor
Name
Address
Country ISO Code

I.2. IMSOC reference

I.2.a. Local reference

I.3. Central Competent Authority

I.4. Local Competent Authority

I.5. Consignee
Name
Address
Country ISO Code

I.6. Operator conducting assembly operations independently of an establishment
Name
Address
Approval Number
Country ISO Code

I.7. Country of origin ISO Code

I.8. Region of origin Code

I.9. Country of destination ISO Code

I.10. Region of destination Code

I.11. Place of dispatch
Name
Address
Approval Number
Country ISO Code

I.12. Place of destination
Name
Address
Approval Number
Country ISO Code

I.13. Place of loading
Name
Address
Approval Number
Country ISO Code

I.14. Date and time of departure

I.15. Means of Transport

Mode	International transport document	Identification

I.16. Transporter
Name
Address
Approval Number
Country ISO Code

I.17. Accompanying documents
Document Type
Accompanying document reference
Date of Issue
Country
Place of issue

I.18. Transport conditions
Chilled ☐ Ambient ☐ Frozen ☐

I.19. Container No / Seal No

I.20. Certified as
Germinal products ☐

I.21. For transit through a third country ☐
Third country ISO Code
Exit point BCP code
Entry point BCP code

I.22. For transit through Member State(s) ☐
Member State ISO Code

I.23. For export ☐
Third country ISO Code
Exit point BCP code

I.24. Estimated journey time

I.25. Journey Log

I.26. Total number of packages	I.27. Total quantity	I.28. Total gross weight

I.30. Description of consignment

1. 05 PRODUCTS OF ANIMAL ORIGIN, NOT ELSEWHERE SPECIFIED OR INCLUDED

0511 Animal products not elsewhere specified or included; dead animals of Chapter 1 or 3, unfit for human consumption

051199 Other

05119985 Other

Part I: Description of consignment

#1.	Commodity	Identification Number	Quantity	Nature of commodity	Identification Mark
Species		Package count	Date of collection / production	Plant / Establishment / Centre	Type

Part II: Certification

II. Health information		

I, the undersigned official veterinarian, hereby certify that:

(1) ☐ [II.1. The ☐ [oocytes] (1) ☐ [in vivo derived embryos] (1) of equine animals described in Part I have been collected, processed and stored, and dispatched by the embryo collection team (2) which:

II.1.1. is approved and kept in a register by the competent authority;

II.1.2. complies with requirements as regards responsibilities, operational procedures, facilities and equipment set out in Part 2 of Annex I to Commission Delegated Regulation (EU) 2020/686.]

(1) ☐ [II.1. The ☐ [oocytes] (1) ☐ [in vitro produced embryos] (1) ☐ [micromanipulated embryos] (1) of equine animals described in Part I have been collected or produced, processed and stored, and dispatched by the embryo production team (2) which:

II.1.1. is approved and kept in a register by the competent authority;

II.1.2. complies with requirements as regards responsibilities, operational procedures, facilities and equipment set out in Parts 2 and 3 of Annex I to Delegated Regulation (EU) 2020/686.]

II.2. The ☐ [oocytes] (1) ☐ [embryos] (1) described in Part I are intended for artificial reproduction and were obtained from donor animals which:

II.2.1. have been born and remained since birth in the Union, or have entered the Union in accordance with the requirements for entry into the Union;

II.2.2. come from establishments in a Member State or zone thereof, or from establishments under official control by the competent authority in a third country or territory, or a zone thereof in which:

II.2.2.1. surra (Trypanosoma evansi) has not been reported during the preceding 30 days prior to the date of ☐ [collection] (1) ☐ [production] (1) of the ☐ [oocytes] (1) ☐ [embryos] (1), and

(1) ○ either [surra has not been reported in the establishment during the preceding 2 years prior to the date of ☐ [collection] (1) ☐ [production] (1) of the ☐ [oocytes] (1) ☐ [embryos] (1);]

(1) ○ or [surra has been reported in the establishment during the preceding 2 years prior to the date of ☐ [collection] (1) ☐ [production] (1) of the ☐ [oocytes] (1) ☐ [embryos] (1) and following the date of the last outbreak, the affected establishment has remained under movement restrictions:

(1) ○ either [until the date on which the remaining animals in the establishment have been subjected to a test for surra with one of the diagnostic methods provided for in Part 3 of Annex I to Commission Delegated Regulation (EU) 2020/688, carried out, with negative results, on samples taken at least 6 months following the date on which the last infected animal has been removed from the establishment;]]

(1) ○ or [for at least 30 days following the date on which the last animal of listed species in the establishment was either killed and destroyed, or slaughtered, and the premises were cleaned and disinfected;]]

II.2.2.2. dourine has not been reported during the preceding 6 months prior to the date of ☐ [collection] (1) ☐ [production] (1) of the ☐ [oocytes] (1) ☐ [embryos] (1), and:

(1) ○ either [dourine has not been reported in the establishment during the preceding 2 years prior to the date of ☐ [collection] (1) ☐ [production] (1) of the ☐ [oocytes] (1) ☐ [embryos] (1);]

(1) ○ or [dourine has been reported in the establishment during the preceding 2 years prior to the date of ☐ [collection] (1) ☐ [production] (1) of the ☐ [oocytes] (1) ☐ [embryos] (1) and following the date of the last outbreak, the affected establishment has remained under movement restrictions:

(1) ○ either [until the date on which the remaining equine animals in the establishment, except castrated male equine animals have been subjected to a test for dourine with the diagnostic method provided for in Part 8 of Annex I to Delegated Regulation (EU) 2020/688, carried out, with negative results, on samples taken at least 6 months following the date on which the infected animals have been killed and destroyed, or slaughtered, or the date on which the infected entire male equine animals have been castrated;]]

(1) ○ or [for at least 30 days following the date on which the last equine animal in the establishment was either killed and destroyed, or slaughtered, and the the premises were cleaned and disinfected;]]

II.2.2.3. equine infectious anaemia: has not been reported during the preceding 90 days prior to the date of ☐ [collection] (1) ☐ [production] (1) of the ☐ [oocytes] (1) ☐ [embryos] (1), and:

(1) ○ either [equine infectious anaemia has not been reported in the establishment during the preceding 12 months prior to the date of ☐ [collection] (1) ☐ [production] (1) of the ☐ [oocytes] (1) ☐ [embryos] (1);]

Part II: Certification

II. Health information		

(1) ○ or [equine infectious anaemia has been reported in the establishment during the preceding 12 months prior to the date of ☐ [collection] (1) ☐ [production] (1) of the ☐ [oocytes] (1) ☐ [embryos] (1) and following date on which the last outbreak, the affected establishment has remained under movement restrictions:

(1) ○ either [until the date on which the remaining equine animals in the establishment have been subjected to a test for equine infectious anaemia with the diagnostic method provided for in Part 9 of Annex I to Delegated Regulation (EU) 2020/688, carried out, with negative results, on samples taken on two occasions with a minimum interval of 3 months following the date on which the infected animals have been killed and destroyed, or slaughtered, and the establishment was cleaned and disinfected;]]

(1) ○ or [for at least 30 days following the date on which the last equine animal in the establishment was either killed and destroyed, or slaughtered, and the premises were cleaned and disinfected;]]

II.2.3. were examined by the team veterinarian or a team member and did not show symptoms or clinical signs of transmissible animal diseases on the date of collection of the ☐ [oocytes] (1) ☐ [embryos] (1);

II.2.4. are identified as provided for in Article 58(1), Article 59(1) or Article 62(1) of Commission Delegated Regulation (EU) 2019/2035;

II.2.5. for at least 30 days prior to the date of first collection of the ☐ [oocytes] (1) ☐ [embryos] (1) and during the collection period:

II.2.5.1. were kept in establishments situated in a zone not subject to movement restrictions established due to the occurrence of African horse sickness, infection with Burkholderia mallei (glanders) or of an emerging disease relevant for equine animals;

II.2.5.2. were kept in establishments where Venezuelan equine encephalomyelitis, dourine, surra (Trypanosoma evansi), equine infections anaemia, contagious equine metritis (Taylorella equigenitalis), infection with rabies virus and anthrax have not been reported;

II.2.5.3. were not in contact with animals from establishments situated in a zone subject to movement restrictions due to the occurrence of diseases referred to in point II.2.5.1 or from establishments which do not meet the conditions referred to in point II.2.5.2;

II.2.6. were not used for natural breeding during at least 30 days prior to the date of collection of the ☐ [oocytes] (1) ☐ [embryos] (1) and between the date of the first samples referred to in points II.2.7.1 and II.2.7.2 and the date of collection of the ☐ [oocytes] (1) ☐ [embryos] (1);

II.2.7. have been subjected to the following tests, referred to in Part 4, Chapter II, points 2(b) and (c), of Annex II to Delegated Regulation (EU) 2020/686, as follows:

II.2.7.1. for equine infectious anaemia (EIA), an agar-gel immuno-diffusion test (AGID or Coggins test) or an enzyme-linked immunosorbent assay (ELISA) with a negative result carried out on a blood sample taken on (3), being not less than 14 days following the date of commencement of the period referred to in point II.2.6 and not more than 90 days prior to the date of the collection of the ☐ [oocytes] (1) ☐ [embryos] (1) intended for movement to another Member State;]

II.2.7.2. for contagious equine metritis (CEM), an agent identification test carried out with a negative result on at least two specimens (swabs) taken during the period referred to in point II.2.6 from at least the mucosal surfaces of the clitoral fossa and the clitoral sinuses of the donor mare

(1) ☐ either [II.2.7.2.1. on two occasions with an interval of not less than 7 days on (3) and on (6), in the case of isolation of Taylorella equigenitalis after cultivation under microaerophilic conditions for at least 7 days, set up within 24 hours after taking the specimens from the donor animal, or 48 hours where the specimens are kept cool during transport.]

(1) ☐ and/or [II.2.7.2.2. on one occasion on (3), in the case of detection of genome of Taylorella equigenitalis by a polymerase chain reaction (PCR) or real-time PCR, carried out within 48 hours after taking the specimens from the donor animal.]

The samples referred to in points II.2.7.2.1 and II.2.7.2.2 were in no case taken earlier than 7 days (systemic treatment) or 21 days (local treatment) after antimicrobial treatment of the donor mares and were placed in transport medium with activated charcoal, such as Amies medium, before dispatch to the laboratory.

II.3. The ☐ [oocytes] (1) ☐ [embryos] (1) described in Part I:

II.3.1. have been collected, processed and stored in accordance with animal health requirements set out in ☐

Part II: Certification

II. Health information

[Part 2] (1) ☐ [Part 3] (1) ☐ [Part 4] (1) ☐ [Part 5] (1) and Part 6 of Annex III to Delegated Regulation (EU) 2020/686;

II.3.2. are placed in straws or other packages on which the mark is applied in accordance with requirements provided for in Article 10 of Delegated Regulation (EU) 2020/686 and that mark is indicated in box I.30;

II.3.3. are transported in a container which:

II.3.3.1. was sealed and numbered prior to the date of dispatch by the embryo collection or production team under responsibility of the team veterinarian, or by an official veterinarian, and the seal bears the number as indicated in box I.19;

II.3.3.2. has been cleaned and either disinfected or sterilised before use, or is single-use container;

(1) (7) ☐ [II.3.3.3. has been filled in with a cryogenic agent which has not been previously used for other products;]

(1) (5) ☐ [II.3.4. are placed in straws or other packages which are securely and hermetically sealed;

II.3.5. are transported in a container where the different types are separated from each other by physical compartments or by being placed in secondary protective bags.]

(1) (6) ☐ [II.4. The ☐ [in vivo derived embryos] (1) ☐ [in vitro produced embryos] (1) ☐ [micromanipulated embryos] (1) described in Part I were conceived by artificial insemination using semen coming from a semen collection centre, germinal product processing establishment or germinal product storage centre approved for the collection, processing and/or storage of semen by the competent authority of a Member State or by the competent authority of a third country or territory, or zone thereof listed in Annex XII to Commission Implementing Regulation (EU) 2021/404, and which was collected, processed and stored in accordance with the requirements of Part 4, Chapter I of Annex II, and of Part 1 of Annex III to Delegated Regulation (EU) 2020/686.]

(1) (7) ☐ [II.5. The following antibiotic or mixture of antibiotics (8) has been added to the collection, processing, washing or storage media:]

II.6. The ☐ [oocytes] (1) ☐ [embryos] (1) described in Part I are dispatched:

(1) ○ either [by an ☐ [embryo collection team] (1) ☐ [embryo production team] (1) or from a zone not subject to movement restrictions affecting equine animals and established for reasons of listed diseases relevant for those species or diseases subject to emergency measures relevant for those species or those restrictions do not apply to these oocytes or embryos because they were collected before the restrictions were established, and they have not been in contact with other oocytes or embryos of a lower health status for an adequate period.]

(1) ○ or [by an ☐ [embryo collection team] (1) ☐ [embryo production team] (1) or from a zone subject to movement restrictions affecting equine animals and established for (9), but derogations from movement restrictions have been granted, and:

(1) ☐ [they comply with the requirements set out in (10);]]

(1) ☐ [and in particular, they are (11).]]

Notes

In accordance with the Agreement on the withdrawal of the United Kingdom of Great Britain and Northern Ireland from the European Union and the European Atomic Energy Community, and in particular Article 5(4) of the Protocol on Ireland/Northern Ireland in conjunction with Annex 2 to that Protocol, references to the Union in this animal health certificate include the United Kingdom in respect of Northern Ireland.

This animal health certificate shall be completed in accordance with the notes for the completion of certificates provided for in Chapter 2 of Annex I to Commission Implementing Regulation (EU) 2020/2235.

Part I:

Box reference I.11: “Place of dispatch”: Indicate the unique approval number and the name and address of the embryo collection or production team of dispatch of the consignment of oocytes or embryos.

Box reference I.12: “Place of destination”: Indicate the address and unique registration or approval number of the establishment of destination of the consignment of oocytes or embryos.

Box Seal number shall be indicated.

Part II: Certification

II. Health information		

reference I.19:

Box reference I.26: Total number of packages shall correspond to the number of containers.

Box reference I.30: “Type”: Specify if in vivo derived embryos, in vivo derived oocytes, in vitro produced embryos or micromanipulated embryos.

“Identification number”: Indicate identification number of each donor animal.

“Identification mark”: Indicate mark on the straw or other packages where the oocytes or embryos of the consignment are placed.

“Date of collection/production”: indicate the date on which the oocytes or embryos of the consignment are collected or produced.

“Approval or registration number of plant/establishment/centre”: Indicate the unique approval number of the embryo collection or production team by which the oocytes or embryos of the consignment were collected or produced.

“Quantity”: Indicate number of straws or other packages with the same mark.

Part II:

(1) Delete if not applicable.

(2) Only embryo collection or production teams approved by the competent authority and included in the register referred to in Article 101(1), point (b), of Regulation (EU) 2016/429 of the European Parliament and of the Council and Article 7 of Delegated Regulation (EU) 2020/686.

(3) Insert date in the following format: dd.mm.yyyy.

(4) Applicable for frozen oocytes or embryos.

(5) Applicable for consignments where oocytes, in vivo derived embryos, in vitro produced embryos and micromanipulated embryos of equine animals are placed and transported in one container.

(6) Does not apply to oocytes.

(7) Mandatory attestation in case antibiotic(s) was/were added.

(8) Insert the name(s) of the antibiotic(s) added and its (their) concentration.

(9) Insert the name of the disease(s).

(10) Insert the specific reference to the article(s), title, and number of the relevant legal act(s) adopted by the Commission providing for those requirements.

(11) Insert the specific attestation(s) provided for in and required by the relevant legal act(s) adopted by the Commission, as referred to in Article 159(2), points (a), (b) and (c), of Regulation (EU) 2016/429.

Certifying Officer/Official veterinarian	
Name (in capital letters)	Qualification and title
Date of declaration	Signature
Stamp	